PT  - JOURNAL ARTICLE
AU  - Melisa M. Shah
AU  - Phillip P. Salvatore
AU  - Laura Ford
AU  - Emiko Kamitani
AU  - Melissa J. Whaley
AU  - Kaitlin Mitchell
AU  - Dustin W. Currie
AU  - Clint N. Morgan
AU  - Hannah E. Segaloff
AU  - Shirley Lecher
AU  - Tarah Somers
AU  - Miriam E. Van Dyke
AU  - John Paul Bigouette
AU  - Augustina Delaney
AU  - Juliana DaSilva
AU  - Michelle O’Hegarty
AU  - Lauren Boyle-Estheimer
AU  - Fatima Abdirizak
AU  - Sandor E. Karpathy
AU  - Jennifer Meece
AU  - Lynn Ivanic
AU  - Kimberly Goffard
AU  - Doug Gieryn
AU  - Alana Sterkel
AU  - Allen Bateman
AU  - Juliana Kahrs
AU  - Kimberly Langolf
AU  - Tara Zochert
AU  - Nancy W. Knight
AU  - Christopher H. Hsu
AU  - Hannah L. Kirking
AU  - Jacqueline E. Tate
TI  - Performance of Repeat BinaxNOW SARS-CoV-2 Antigen Testing in a Community Setting, Wisconsin, November-December 2020
AID  - 10.1101/2021.04.05.21254834
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.05.21254834
4099  - http://medrxiv.org/content/early/2021/04/09/2021.04.05.21254834.short
4100  - http://medrxiv.org/content/early/2021/04/09/2021.04.05.21254834.full
AB  - Repeating the BinaxNOW antigen test for SARS-CoV-2 by two groups of readers within 30 minutes resulted in high concordance (98.9%) in 2,110 encounters. BinaxNOW test sensitivity was 77.2% (258/334) compared to real-time reverse transcription-polymerase chain reaction. Repeating antigen testing on the same day did not significantly improve test sensitivity while specificity remained high.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. See e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. 241(d); 5 U.S.C. 552a; 44 U.S.C. 3501 et seq.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonable request.